Expert Opinion on Pharmacotherapy最新文献_第3页

Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder. 阿片类药物使用障碍患者的药物和行为疼痛治疗策略。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-17 DOI: 10.1080/14656566.2025.2506688

Victoria Ameral, Thomas R Hickey, Erin Dawna Reilly, Jessica A Patterson, Mehmet Sofuoglu

{"title":"Pharmacological and behavioral pain treatment strategies for patients with opioid use disorder.","authors":"Victoria Ameral, Thomas R Hickey, Erin Dawna Reilly, Jessica A Patterson, Mehmet Sofuoglu","doi":"10.1080/14656566.2025.2506688","DOIUrl":"10.1080/14656566.2025.2506688","url":null,"abstract":"Introduction: A critical challenge in providing effective medical care for individuals in opioid agonist treatment (OAT) for opioid use disorder is the effective management of acute and chronic pain. While pain commonly co-occurs with opioid use disorder, there is limited research to guide effective management of pain in this population.Areas covered: We first provide an overview of the etiology and treatment of acute and chronic pain, highlighting areas of complexity for patients receiving OAT. We then describe the search strategy, which involved a date-inclusive search for relevant terms in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials. After summarizing the results of this search on the evidence for pharmacological and behavioral treatments of acute and chronic pain for individuals on OAT, we conclude with a discussion of these findings and a summarized expert opinion on the state of the evidence.Expert opinion: The evidence suggests that while research on effective treatment of acute and chronic pain in individuals in OAT is limited, promising work is ongoing to translate existing treatments, particularly behavioral treatments for chronic pain, to support this population. However, further research is warranted, particularly regarding pharmacological options.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1041-1054"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sepiapterin for the treatment of phenylketonuria. 七蝶呤治疗苯丙酮尿症。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-04-30 DOI: 10.1080/14656566.2025.2498477

Robin A Williams, Damon A Bell, Amanda J Hooper, John R Burnett

{"title":"Sepiapterin for the treatment of phenylketonuria.","authors":"Robin A Williams, Damon A Bell, Amanda J Hooper, John R Burnett","doi":"10.1080/14656566.2025.2498477","DOIUrl":"10.1080/14656566.2025.2498477","url":null,"abstract":"Introduction: Phenylketonuria (PKU) is an autosomal recessive inborn error of phenylalanine (Phe) metabolism resulting from deficiency of phenylalanine hydroxylase (PAH). Untreated, PKU may result in severe and irreversible intellectual impairment due to marked hyperphenylalaninemia (HPA). Guidelines recommend lifelong reduction in Phe levels, usually achieved via a strict low-protein diet and sometimes medications.Areas covered: We discuss the role of tetrahydrobiopterin (BH4), an essential PAH cofactor in Phe metabolism, describe the pharmacodynamics, pharmacokinetics, and metabolism of sepiapterin, as well as reporting on its efficacy and safety in children and adults with PKU.Expert opinion: Sepiapterin, an oral synthetic form of a natural precursor of BH4, can reduce HPA in some patients with PKU. In relatively short-term studies, sepiapterin has been shown to be safe, well tolerated, and like the BH4 analog sapropterin dihydrochloride effective in reducing blood Phe levels in responsive individuals. The reductions in blood Phe observed with sepiapterin in the phase III APHENITY trial has the potential to allow more PKU patients to attain Phe treatment targets or alternatively easing of the onerous dietary Phe restrictions. Results of longer-term studies in patients with PKU, including neurocognitive and functional outcomes, nutritional status, and quality of life are awaited.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"933-938"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in understanding migraine for the development of novel pharmacotherapies: the use of human provocation migraine models. 了解偏头痛的新药物治疗进展：人类诱发偏头痛模型的使用。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-06-09 DOI: 10.1080/14656566.2025.2505231

Nazia Karsan, Sina Marzoughi, Peter J Goadsby

{"title":"Advances in understanding migraine for the development of novel pharmacotherapies: the use of human provocation migraine models.","authors":"Nazia Karsan, Sina Marzoughi, Peter J Goadsby","doi":"10.1080/14656566.2025.2505231","DOIUrl":"10.1080/14656566.2025.2505231","url":null,"abstract":"Introduction: Whilst migraine treatment has advanced significantly over recent times, the mechanisms of attack genesis and heterogeneity in treatment response are two amidst several areas that remain poorly understood and require further development. Experimental migraine provocation is an area that holds promise in advancing this understanding.Areas covered: We conducted a literature search using PubMed, of 'human migraine triggering' and 'human migraine provocation', to identify articles of interest. We discuss therapeutic targets that have emerged from such work, including calcitonin family peptides amylin (AMY) and adrenomedullin (ADM), pituitary adenylate cyclase-activating polypeptide (PACAP), and potassium channels. We discuss our views on the clinical translation of the outcomes of such studies, and their previous and potential future impact on migraine therapeutics.Expert opinion: Migraine provocation models provide a valuable means to study human migraine phenotypically and biologically, as well as to assess treatment response. Downstream intracellular mechanisms of provocation agents can be targeted during cellular processing to alter cell function and influence migraine mechanisms. It is important to caveat the clinical translation of provocation studies, given that just because a substance triggers migraine experimentally, does not necessarily mean that the substance is involved in the spontaneous human condition.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1021-1040"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143970432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A subgroup analysis of the MiroCIP study to evaluate chemotherapy-induced peripheral neuropathy: symptom profile, severity, and analgesia efficacy depending on type of chemotherapy. 评估化疗引起的周围神经病变的MiroCIP研究的亚组分析：症状概况，严重程度和镇痛效果取决于化疗类型。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-19 DOI: 10.1080/14656566.2025.2499665

Sonoko Misawa, Takahiro Kogawa, Yoichi Naito, Takuji Suzuki, Mamoru Takada, Tadamichi Denda, Aoi Hino, Tomoki Suichi, Sho Kodama, Arisa Miyoshi, Kazuhito Shiosakai, Satoshi Kuwabara

{"title":"A subgroup analysis of the MiroCIP study to evaluate chemotherapy-induced peripheral neuropathy: symptom profile, severity, and analgesia efficacy depending on type of chemotherapy.","authors":"Sonoko Misawa, Takahiro Kogawa, Yoichi Naito, Takuji Suzuki, Mamoru Takada, Tadamichi Denda, Aoi Hino, Tomoki Suichi, Sho Kodama, Arisa Miyoshi, Kazuhito Shiosakai, Satoshi Kuwabara","doi":"10.1080/14656566.2025.2499665","DOIUrl":"10.1080/14656566.2025.2499665","url":null,"abstract":"Background: The multicenter, prospective MiroCIP observational study investigated the incidence, risk factors, and outcomes of chemotherapy-induced peripheral neuropathy (CIPN) by oxaliplatin- and taxane-based chemotherapies but did not examine their differences in detail. This post hoc subanalysis explored the differences between oxaliplatin- and taxane-based chemotherapy, in terms of CIPN symptom profile, severity, and response to analgesics.Research design and methods: Patients with colorectal, gastric, non-small cell lung, or breast cancer, scheduled to receive oxaliplatin- or taxane-based chemotherapy, were followed for 12 months to assess the severity of sensory CIPN, by the Common Terminology Criteria for Adverse Events, and associated subjective and objective symptoms.Results: Overall, 91 patients received oxaliplatin and 131 received a taxane. At 12 months, CIPN prevalence was 74.6% with oxaliplatin and 55.2% with a taxane. Grade ≥ 2 CIPN peaked at 9 months with oxaliplatin and at 3 months with a taxane, with most symptom scores following a similar trajectory. Analgesic efficacy differed between subgroups, providing marked reductions in pain/tingling scores in the taxane group but minimal effect in the oxaliplatin group.Conclusions: CIPN course and symptoms vary with oxaliplatin- or taxane-based chemotherapy. Effective management should be tailored to the type of chemotherapy: oxaliplatin-treated patients may benefit from continuous monitoring of CIPN symptoms, whereas it may be beneficial for taxane-treated patients to receive appropriate analgesics at CIPN onset.Trial registration: Japan Registry of Clinical Trials jRCTs031210101.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"979-989"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Conditional marketing authorisation of therapeutic medicines for solid tumours in the European Union: methodological and clinical challenges. 欧盟实体肿瘤治疗药物的有条件上市许可：方法学和临床挑战

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-11 DOI: 10.1080/14656566.2025.2504699

Stefania Bellino, Anna La Salvia

引用次数: 0

Selecting appropriate therapy for cutaneous T-cell lymphomas (CTCLs): recent advances and the unmet need. 选择合适的治疗皮肤t细胞淋巴瘤（ctcl）：最近的进展和未满足的需求。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-14 DOI: 10.1080/14656566.2025.2503850

Sayan Poursadrolah, Ruba Alchaikh Hassan, Ion Codreanu, Constantin A Dasanu

引用次数: 0

Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies. 结核病和糖尿病之间的临床、代谢和免疫相互作用：治疗的意义和机会。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-26 DOI: 10.1080/14656566.2025.2508904

Itai M Magodoro, Leigh A Kotze, Cari J Stek, Alexander West, Andrea Le Roux, Nadja Sobratee, Arshad Taliep, Yohhei Hamada, Joel A Dave, Molebogeng X Rangaka, Suraj P Parihar, Robert J Wilkinson

{"title":"Clinical, metabolic, and immune interaction between tuberculosis and diabetes mellitus: implications and opportunities for therapies.","authors":"Itai M Magodoro, Leigh A Kotze, Cari J Stek, Alexander West, Andrea Le Roux, Nadja Sobratee, Arshad Taliep, Yohhei Hamada, Joel A Dave, Molebogeng X Rangaka, Suraj P Parihar, Robert J Wilkinson","doi":"10.1080/14656566.2025.2508904","DOIUrl":"10.1080/14656566.2025.2508904","url":null,"abstract":"Introduction: Tuberculosis (TB) remains a major infectious threat to global health, while type 2 diabetes mellitus (diabetes) has reached epidemic proportions in many regions of the world. In low- and middle-income countries (LMIC) and among indigenous and minority communities in high-income settings (HIC), these diseases also increasingly overlap, posing new clinical and therapeutic challenges.Areas covered: We searched PubMed/CINAHL/Web of Science/Scopus, Google Scholar up to 30 November 2024. Meanwhile, the Immuno-metabolic parallels between TB and Diabetes are underappreciated. Improved understanding of mechanisms may pave the way for novel therapeutic strategies, for example, using antidiabetic medications as adjuvant host-directed therapies (HDT) in active TB. We review the epidemiology of TB, diabetes and their combined comorbidity, their immune and metabolic mechanisms and clinical relevance, as well as potential opportunities for general and targeted therapeutic intervention.Expert opinion: Immunometabolic interaction between diabetes and tuberculosis is bidirectional. Underlying this interaction are shared inflammatory mechanisms. It follows that treatments for diabetes and its complication may be beneficial in tuberculosis and that the treatment of both active and latent tuberculosis may improve glycemic control. These interactions are amenable to investigation in experimental models, in human experimental medicine studies and in clinical trials.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1099-1112"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Selecting optimal therapy for advanced non-functional pancreatic neuroendocrine tumors: latest research and therapeutic advances. 晚期非功能性胰腺神经内分泌肿瘤的最佳治疗选择：最新研究和治疗进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-07 DOI: 10.1080/14656566.2025.2501142

Ruba Alchaikh Hassan, Arti Patel, Constantin A Dasanu

引用次数: 0

Selecting optimal therapy in systemic mastocytosis: current state and future directions. 选择全身性肥大细胞增多症的最佳治疗方法：现状和未来方向。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-12 DOI: 10.1080/14656566.2025.2503847

Ifeoma Ike, Victor Samperio, Constantin A Dasanu

引用次数: 0

Beyond the injection: delivery systems reshaping retinal disease management. 注射之外：传递系统重塑视网膜疾病管理。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2025-06-01 Epub Date: 2025-05-11 DOI: 10.1080/14656566.2025.2496424

Lucas W Rowe, Christian Akotoye, Alon Harris, Thomas A Ciulla

{"title":"Beyond the injection: delivery systems reshaping retinal disease management.","authors":"Lucas W Rowe, Christian Akotoye, Alon Harris, Thomas A Ciulla","doi":"10.1080/14656566.2025.2496424","DOIUrl":"10.1080/14656566.2025.2496424","url":null,"abstract":"Introduction: Intravitreal injections remain the standard for treating common retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy. However, frequent administration creates significant treatment burden due to limited drug half-life and the chronic nature of these conditions.Areas covered: This review summarizes emerging drug delivery techniques and therapies for retinal disease that have achieved FDA approval within the past five years or have advanced to Phase 3 development, including intravitreal sustained-release platforms and alternative delivery routes (suprachoroidal, subretinal, topical, and subcutaneous). Specific innovations discussed include the ranibizumab port delivery system, EYP-1901 (Duravyu, vorolanib implant), KSI-301 (tarcocimab tedromer), KSI-501, OTX-TKI (Axpaxli, axitinib implant), 4D-150, revakinagene taroretcel-lwey (Encelto, NT-501, encapsulated cell therapy), Xipere (triamcinolone acetonide injectable suspension), AU-011 (belzupacap sarotalocan targeted delivery), ABBV-RGX-314, elamipretide, and OCS-01 (high concentration dexamethasone).Expert opinion: Promising innovations include sustained-release intravitreal implants, topical and subcutaneous delivery systems, and targeted methods like suprachoroidal and subretinal injections, each with unique advantages and limitations. Challenges include overcoming the blood-retinal barrier, surgical complications with implantable devices, and ensuring patient adherence. Advances in smart delivery systems, drug formulations, and predictive models, alongside interdisciplinary collaboration, will be crucial in achieving personalized, effective, and sustainable retinal therapies.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"939-952"},"PeriodicalIF":2.5,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0